FibroGen, Inc (NASDAQ:FGEN) insider K Peony Yu sold 2,851 shares of the firm’s stock in a transaction that occurred on Thursday, September 14th. The stock was sold at an average price of $51.00, for a total transaction of $145,401.00. Following the transaction, the insider now owns 185,546 shares of the company’s stock, valued at approximately $9,462,846. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

K Peony Yu also recently made the following trade(s):

  • On Monday, August 21st, K Peony Yu sold 7,500 shares of FibroGen stock. The stock was sold at an average price of $41.03, for a total transaction of $307,725.00.
  • On Tuesday, August 8th, K Peony Yu sold 37,500 shares of FibroGen stock. The stock was sold at an average price of $50.58, for a total transaction of $1,896,750.00.
  • On Tuesday, August 1st, K Peony Yu sold 10,000 shares of FibroGen stock. The stock was sold at an average price of $33.48, for a total transaction of $334,800.00.
  • On Monday, July 10th, K Peony Yu sold 5,000 shares of FibroGen stock. The stock was sold at an average price of $32.98, for a total transaction of $164,900.00.

FibroGen, Inc (FGEN) traded up 0.58% during mid-day trading on Friday, hitting $52.40. 1,462,946 shares of the stock traded hands. FibroGen, Inc has a 1-year low of $15.60 and a 1-year high of $52.70. The company has a 50-day moving average of $42.78 and a 200 day moving average of $31.87. The firm’s market capitalization is $3.73 billion.

FibroGen (NASDAQ:FGEN) last announced its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.48) EPS for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.01). FibroGen had a negative return on equity of 64.42% and a negative net margin of 105.59%. The business had revenue of $29.00 million during the quarter, compared to analysts’ expectations of $34.80 million. On average, equities research analysts anticipate that FibroGen, Inc will post ($1.80) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This piece was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another site, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2017/09/15/k-peony-yu-sells-2851-shares-of-fibrogen-inc-fgen-stock.html.

Hedge funds have recently made changes to their positions in the stock. Quantbot Technologies LP purchased a new stake in FibroGen in the second quarter worth $128,000. Ameritas Investment Partners Inc. purchased a new stake in FibroGen in the first quarter worth $111,000. SG Americas Securities LLC lifted its stake in FibroGen by 6.5% in the second quarter. SG Americas Securities LLC now owns 6,747 shares of the biopharmaceutical company’s stock worth $218,000 after acquiring an additional 412 shares during the period. Amalgamated Bank purchased a new stake in FibroGen in the second quarter worth $237,000. Finally, BNP Paribas Arbitrage SA lifted its stake in FibroGen by 589.1% in the second quarter. BNP Paribas Arbitrage SA now owns 7,401 shares of the biopharmaceutical company’s stock worth $239,000 after acquiring an additional 6,327 shares during the period. 47.49% of the stock is owned by institutional investors.

FGEN has been the subject of several analyst reports. Stifel Nicolaus restated a “buy” rating and set a $38.00 price target (up previously from $32.00) on shares of FibroGen in a report on Thursday, June 22nd. Jefferies Group LLC restated a “buy” rating and set a $75.00 price target on shares of FibroGen in a report on Tuesday. Citigroup Inc. restated a “buy” rating and set a $48.00 price target on shares of FibroGen in a report on Monday, June 26th. BidaskClub lowered shares of FibroGen from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Finally, Goldman Sachs Group, Inc. (The) lowered shares of FibroGen from a “buy” rating to a “neutral” rating and set a $31.00 price objective for the company. in a research note on Friday, July 21st. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. FibroGen has an average rating of “Buy” and an average price target of $60.17.

About FibroGen

FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.

Insider Buying and Selling by Quarter for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related companies with MarketBeat.com's FREE daily email newsletter.